Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 19/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 19/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579414 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15807233 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL29707895 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2240264 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL8186716 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3898784 | 1.00 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL22408649 | 0.99 | OPRL1 (0.98) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL7885527 | 0.99 | OPRL1 (0.98) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL7883807 | 0.92 | OPRL1 (0.84) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6834468 | 0.87 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-19 | — | — | US | claimed |
| US-20030032651-A1 | Intrathecal analgesia method | OMEROS CORPORATION | 2003-02-13 | — | — | US | claimed |
| US-20150290211-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8003669-B2 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7737118-B2 | Rotational intrathecal analgesia | OMEROS CORPORATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090253747-A1 | Remedy for sleep disturbance | TESHIMA KOJI | 2009-10-08 | — | — | US | disclosed |
| US-7566728-B2 | Advance circadian rhythm disorders; using opioid receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070299687-A1 | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed | ACELRX PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20050119308-A1 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1406629-A1 | METHOD FOR INDUCING ANALGESIA COMPRISING ADMINISTRATION ALTERNATIVELY OF AN OPIOID RECEPTOR AGONIST AND AN OPIOID RECEPTOR LIKE RECEPTOR 1 AGONIST FOR AND AN IMPLANTABLE INFUSION PUMP | Omeros Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030040479-A1 | Rotational intrathecal analgesia method and device | OMEROS CORPORATION | 2003-02-27 | — | — | US | disclosed |
| US-20030040486-A1 | Rotational intrathecal analgesia | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-02-27 | — | — | US | disclosed |
| US-20030032651-A1 | Intrathecal analgesia method | OMEROS CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-20030032651-A1 | Intrathecal analgesia method | OMEROS CORPORATION | 2003-02-13 | — | — | US | disclosed |
| WO-2003004034-A1 | METHOD FOR INDUCING ANALGESIA COMPRISING ADMINISTRATION ALTERNATIVELY OF AN OPIOID RECEPTOR AGONIST AND AN OPIOID RECEPTOR LIKE RECEPTOR 1 AGONIST FOR AND AN IMPLANTABLE INFUSION PUMP | OMEROS CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119308-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
| US-20090253747-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
| US-20140171466-A1 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA | OPRL1, OPRM1, OPRK1 | OPRL1 1/4885OPRM1 2/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.